DAFNA Capital Management LLC Decreases Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

DAFNA Capital Management LLC lowered its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 78.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 127,000 shares of the company's stock after selling 462,561 shares during the quarter. DAFNA Capital Management LLC owned about 0.14% of Aquestive Therapeutics worth $452,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. New York State Common Retirement Fund boosted its position in Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock valued at $43,000 after buying an additional 10,700 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Aquestive Therapeutics during the fourth quarter valued at about $44,000. PKS Advisory Services LLC bought a new position in shares of Aquestive Therapeutics during the fourth quarter valued at about $63,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Aquestive Therapeutics during the fourth quarter valued at about $69,000. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Aquestive Therapeutics by 16.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company's stock valued at $99,000 after acquiring an additional 3,821 shares during the last quarter. Institutional investors own 32.45% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on AQST shares. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Wednesday, April 2nd. Raymond James set a $7.00 target price on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Alliance Global Partners reaffirmed a "buy" rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Finally, Lake Street Capital decreased their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $10.67.

Aquestive Therapeutics Trading Down 22.1%

Shares of AQST traded down $0.63 during mid-day trading on Tuesday, hitting $2.22. The company's stock had a trading volume of 7,057,812 shares, compared to its average volume of 1,475,268. The company's 50-day moving average is $2.78 and its 200-day moving average is $3.43. Aquestive Therapeutics, Inc. has a 52-week low of $2.13 and a 52-week high of $5.80. The firm has a market capitalization of $220.49 million, a price-to-earnings ratio of -4.93 and a beta of 2.02.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The company had revenue of $8.72 million for the quarter, compared to analysts' expectations of $12.23 million. As a group, sell-side analysts predict that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.